Risks associated with tiotropium in chronic obstructive pulmonary disease: Overview of the evidence to date

Yoon K. Loke, Sonal Singh

Research output: Contribution to journalArticle

Abstract

Tiotropium is a long-acting inhaled anticholinergic agent that is widely used in the treatment of chronic obstructive pulmonary disease (COPD). It was initially launched as the tiotropium HandiHaler formulation, but this was followed by a newer version based on a potentially more efficient drug delivery device, known as Respimat. This Respimat formulation is available worldwide but has not yet succeeded in gaining regulatory approval in the USA. In the past few years, the adverse effects profile of tiotropium has come under close scrutiny owing to concerns about the possibility of urinary and cardiovascular adverse effects. These concerns appeared to have been alleviated following the publication of data from the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, which was a large trial of 4 years' duration. This trial did not show any excess myocardial infarction, renal or urinary adverse events with tiotropium compared with placebo. However, the risk of urinary retention has been in the spotlight again following publication of two observational studies reporting a significantly increased risk of urinary retention in men recently started on inhaled anticholinergics, especially when prostatic hyperplasia coexists. More recently, a meta-analysis of mortality data for the tiotropium Respimat formulation raised the possibility of an increased risk of death, including death from cardiovascular causes. It is unclear if the more efficient drug delivery offered by the Respimat device is hitting a different part of the dose-toxicity curve. In the absence of any evidence of superior clinical efficacy with tiotropium Respimat compared with tiotropium HandiHaler, some experts have argued that there is no compelling reason to choose the Respimat formulation given the new uncertainties about its safety profile.

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalTherapeutic Advances in Drug Safety
Volume3
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Chronic Obstructive Pulmonary Disease
Urinary Retention
Cholinergic Antagonists
Publications
Equipment and Supplies
Tiotropium Bromide
Prostatic Hyperplasia
Pharmaceutical Preparations
Uncertainty
Observational Studies
Meta-Analysis
Cause of Death
Myocardial Infarction
Placebos
Kidney
Safety
Mortality

Keywords

  • cardiovascular event
  • formulation
  • mortality
  • risk
  • safety
  • tiotropium

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Risks associated with tiotropium in chronic obstructive pulmonary disease : Overview of the evidence to date. / Loke, Yoon K.; Singh, Sonal.

In: Therapeutic Advances in Drug Safety, Vol. 3, No. 3, 06.2012, p. 123-131.

Research output: Contribution to journalArticle

@article{4825df41e8cc49faa334a155f2494987,
title = "Risks associated with tiotropium in chronic obstructive pulmonary disease: Overview of the evidence to date",
abstract = "Tiotropium is a long-acting inhaled anticholinergic agent that is widely used in the treatment of chronic obstructive pulmonary disease (COPD). It was initially launched as the tiotropium HandiHaler formulation, but this was followed by a newer version based on a potentially more efficient drug delivery device, known as Respimat. This Respimat formulation is available worldwide but has not yet succeeded in gaining regulatory approval in the USA. In the past few years, the adverse effects profile of tiotropium has come under close scrutiny owing to concerns about the possibility of urinary and cardiovascular adverse effects. These concerns appeared to have been alleviated following the publication of data from the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, which was a large trial of 4 years' duration. This trial did not show any excess myocardial infarction, renal or urinary adverse events with tiotropium compared with placebo. However, the risk of urinary retention has been in the spotlight again following publication of two observational studies reporting a significantly increased risk of urinary retention in men recently started on inhaled anticholinergics, especially when prostatic hyperplasia coexists. More recently, a meta-analysis of mortality data for the tiotropium Respimat formulation raised the possibility of an increased risk of death, including death from cardiovascular causes. It is unclear if the more efficient drug delivery offered by the Respimat device is hitting a different part of the dose-toxicity curve. In the absence of any evidence of superior clinical efficacy with tiotropium Respimat compared with tiotropium HandiHaler, some experts have argued that there is no compelling reason to choose the Respimat formulation given the new uncertainties about its safety profile.",
keywords = "cardiovascular event, formulation, mortality, risk, safety, tiotropium",
author = "Loke, {Yoon K.} and Sonal Singh",
year = "2012",
month = "6",
doi = "10.1177/2042098612438388",
language = "English (US)",
volume = "3",
pages = "123--131",
journal = "Therapeutic Advances in Drug Safety",
issn = "2042-0986",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Risks associated with tiotropium in chronic obstructive pulmonary disease

T2 - Overview of the evidence to date

AU - Loke, Yoon K.

AU - Singh, Sonal

PY - 2012/6

Y1 - 2012/6

N2 - Tiotropium is a long-acting inhaled anticholinergic agent that is widely used in the treatment of chronic obstructive pulmonary disease (COPD). It was initially launched as the tiotropium HandiHaler formulation, but this was followed by a newer version based on a potentially more efficient drug delivery device, known as Respimat. This Respimat formulation is available worldwide but has not yet succeeded in gaining regulatory approval in the USA. In the past few years, the adverse effects profile of tiotropium has come under close scrutiny owing to concerns about the possibility of urinary and cardiovascular adverse effects. These concerns appeared to have been alleviated following the publication of data from the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, which was a large trial of 4 years' duration. This trial did not show any excess myocardial infarction, renal or urinary adverse events with tiotropium compared with placebo. However, the risk of urinary retention has been in the spotlight again following publication of two observational studies reporting a significantly increased risk of urinary retention in men recently started on inhaled anticholinergics, especially when prostatic hyperplasia coexists. More recently, a meta-analysis of mortality data for the tiotropium Respimat formulation raised the possibility of an increased risk of death, including death from cardiovascular causes. It is unclear if the more efficient drug delivery offered by the Respimat device is hitting a different part of the dose-toxicity curve. In the absence of any evidence of superior clinical efficacy with tiotropium Respimat compared with tiotropium HandiHaler, some experts have argued that there is no compelling reason to choose the Respimat formulation given the new uncertainties about its safety profile.

AB - Tiotropium is a long-acting inhaled anticholinergic agent that is widely used in the treatment of chronic obstructive pulmonary disease (COPD). It was initially launched as the tiotropium HandiHaler formulation, but this was followed by a newer version based on a potentially more efficient drug delivery device, known as Respimat. This Respimat formulation is available worldwide but has not yet succeeded in gaining regulatory approval in the USA. In the past few years, the adverse effects profile of tiotropium has come under close scrutiny owing to concerns about the possibility of urinary and cardiovascular adverse effects. These concerns appeared to have been alleviated following the publication of data from the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, which was a large trial of 4 years' duration. This trial did not show any excess myocardial infarction, renal or urinary adverse events with tiotropium compared with placebo. However, the risk of urinary retention has been in the spotlight again following publication of two observational studies reporting a significantly increased risk of urinary retention in men recently started on inhaled anticholinergics, especially when prostatic hyperplasia coexists. More recently, a meta-analysis of mortality data for the tiotropium Respimat formulation raised the possibility of an increased risk of death, including death from cardiovascular causes. It is unclear if the more efficient drug delivery offered by the Respimat device is hitting a different part of the dose-toxicity curve. In the absence of any evidence of superior clinical efficacy with tiotropium Respimat compared with tiotropium HandiHaler, some experts have argued that there is no compelling reason to choose the Respimat formulation given the new uncertainties about its safety profile.

KW - cardiovascular event

KW - formulation

KW - mortality

KW - risk

KW - safety

KW - tiotropium

UR - http://www.scopus.com/inward/record.url?scp=84868655453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868655453&partnerID=8YFLogxK

U2 - 10.1177/2042098612438388

DO - 10.1177/2042098612438388

M3 - Article

C2 - 25083231

AN - SCOPUS:84868655453

VL - 3

SP - 123

EP - 131

JO - Therapeutic Advances in Drug Safety

JF - Therapeutic Advances in Drug Safety

SN - 2042-0986

IS - 3

ER -